Pay in 4 interest-free payments of $7.31 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Having support systems in place, whether friends, family, online communities, or healthcare providers, makes a meaningful difference in treatment persistence
Patients should consult with their healthcare provider before starting this medication.
The earliest it could hit the market would be late 2026, though it's more likely to drop in 2027
It runs the intake questionnaire, connects patients with independent providers, manages billing, and coordinates with pharmacies
The medication may also have direct anti-inflammatory effects
Retatrutide is an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously a mechanism that sets it apart from existing licensed treatments
US$ 27.87
US$ 24.95
US$ 25.32
US$ 26.44
US$ 28.47
US$ 26.03
US$ 26.17
US$ 24.35
